FOCUS on Dyslipidaemias

Atherosclerotic cardiovascular disease is the most common cause of deaths globally. The primary event instigating atherogenesis is the retention of low-density lipoprotein cholesterol (LDL-C) within the arterial wall. Clinical trials have firmly established that lowering plasma LDL-C has beneficial effects on the prognosis of cardiovascular diseases, and that there is no lower limit of LDL-C known to be unsafe. The 2019 ESC/EAS Guidelines for the management of dyslipidaemias have established the definite causality of LDL-C in atherosclerotic cardiovascular diseases and have incorporated the use of novel treatments.